ArticleArchives of dermatological research2025
LINC01711 modulates proliferation, migration, and extracellular matrix deposition of hypertrophic scar fibroblasts by targeting miR-34a-5p.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fibrotic Disease of the Skin and Lung: Shared Pathways, Environmental Drivers, and Therapeutic Opportunities in a Changing Climate.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic scar (HS) is a proliferative disorder that occurs after skin injury and generally leads to disfigurement and impaired skin function in patients. This study aims to delve into the biological role of long intergenic non-protein coding RNA 1711 (LINC01711) in HS, thereby identifying novel therapeutic approaches for HS. HS tissues and corresponding normal tissues were obtained from 35 patients. The expression of LINC01711 was evaluated by qRT-PCR. The effect of LINC01711 knockdown on HS fibroblasts (HSFs) was measured by CCK-8 assay, migration assay, and apoptosis assay. The molecular mechanisms were investigated through bioinformatics analysis and dual-luciferase reporter assay. The impact of LINC01711 on the expression of extracellular matrix (ECM) deposition markers was measured using ELISA assay. LINC01711 was upregulated in HS tissues and positively correlated with disease severity. The silencing of LINC01711 induced the suppression of cell viability, migration, and the promotion of apoptosis in HSFs. LINC01711 negatively modulated microRNA-34a-5p (miR-34a-5p) expression. Suppression of miR-34a-5p reversed the biological function of LINC01711 knockdown in HSFs. Furthermore, LINC01711 modulated collagen type I alpha 1 chain (COL1A1), tissue inhibitor of metalloprotease-1 (TIMP1), and actin alpha 2 (Acta2) expression in HSFs mediated by miR-34a-5p. The results demonstrated that LINC01711 functioned as a regulatory factor in the proliferation, migration, apoptosis, and ECM deposition of HSFs mediated by miR-34a-5p.
Indexed as
Identifiers
40278926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.